AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15580395
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered s.c. in fasted state
Trial: 15580395
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered s.c. after semiliquid test meal
Trial: 11245552
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptive (DSG-OC)
Trial: 8359179
Drug: Quinidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (250 mg bisulfate) co-administration with Haloperidol (5 mg)
Trial: 8359179
Drug: Quinidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (250 mg bisulfate) co-administration with Reduced Haloperidol (5 mg)
Trial: 8359179
Drug: Quinidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (250 mg bisulfate) co-administration
Trial: 8359179
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg) and Reduced Haloperidol (5 mg)
Trial: 3521427
Drug: T-cell-depleted bone
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell-depleted bone marrow (using monoclonal anti-T-cell antibody CT-2 and complement)
Trial: 31275597
Drug: Lorcaserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin (10 mg twice daily)
Trial: 26402941
Drug: Enteral oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral oxygen therapy (oxygen smoothies based on protein-carbohydrate raw materials with dietary fiber), 500 ml daily for 10 days.
Trial: 26402941
Drug: Enteral oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral oxygen therapy (oxygen smoothies)
Trial: 18805509
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID) call schedule
Trial: 18805509
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) call schedule
Trial: 18805509
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily (TID) call schedule
Trial: 17144555
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment including physical factors (ultrasound, sinusoidal modulated currents‐‐SMC) and medicinal suppositories (diklofenak, vitaprost, polyoxidonium)
Trial: 17144555
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of physical factors and medicinal suppositories
Trial: 11147908
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine administration
Trial: 19411798
Drug: RLG (rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLG (rocuronium 0.6 mg/kg mixed with 2 mL of 2% lidocaine)
Trial: 19411798
Drug: RSG (rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG (rocuronium 0.6 mg/kg with 8.4% sodium bicarbonate)
Trial: 19411798
Drug: RG (rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG (rocuronium 0.6 mg/kg)
Trial: 17493669
Drug: NACT+RHPPL (vincristine-cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACT+RHPPL (vincristine-cisplatin chemotherapy every 10 days for 3 cycles before RHPPL)
Trial: 11840766
Drug: Attenuated live
RxNorm normalized name: Influenza Virus Attenuated Live Trivalent Vaccine (Types A and B) (Avian)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated live hepatitis A vaccine (H2 strain) - 10(6.5) TCID50/ml
Trial: 30910634
Drug: Coated tablets
RxNorm normalized name: psyllium seed coatings,blond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated tablets
Trial: 30910634
Drug: Uncoated tablet
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uncoated tablet
Trial: 24070104
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy for Primary Care (PST‐PC), delivered in 8 weekly telephone sessions of 30-45 minutes duration and 4 monthly maintenance sessions.
Trial: 24070104
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (referral to general practitioner for assessment and treatment)
Trial: 22443122
Drug: No surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surface treatment
Trial: 16777920
Drug: Zinc carnosine
RxNorm normalized name: Zinc Carnosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc carnosine (ZnC) 37.5 mg twice daily
Trial: 11794219
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent split‐virus influenza vaccine
Trial: 7819733
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 1 mg betamethasone disodium phosphate and 250 mg piperacillin (group 2)
Trial: 3337463
Drug: Albuterol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (4 mg three times daily for 3 days)
Trial: 26307337
Drug: Postural manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postural manual therapy (PMT)
Trial: 23879752
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (600 mg loading dose followed by 75 mg/day, with open-label aspirin 50-325 mg/day, recommended 162 mg for 5 days then 81 mg daily)
Trial: 23879752
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (50-325 mg/day, with a recommended dose of 162 mg for 5 days then 81 mg daily)
Trial: 20953211
Drug: rhTNFR-Fc 12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNFR-Fc 12.5, 25, 37.5, or 50 mg SC injection (healthy volunteers)
Trial: 20953211
Drug: rhTNFR-Fc 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNFR-Fc 25 mg BIW or 50 mg QW (patients with AS)
Trial: 18853110
Drug: Kushenin 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kushenin 0.6 g once a day
Trial: 16649350
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg) for 3 months
Trial: 14662554
Drug: Haloperidol (3-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3-15 mg/d)
Trial: 8769301
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU IFN daily until HCV-RNA was undetectable in plasma X 3 over 3 consecutive monthly determinations followed by demonstrated HCV-RNA negativity in liver biopsy tissue
Trial: 1570963
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline containing 10 U per 1 mL heparin
Trial: 6099649
Drug: Towne live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Towne live, attenuated cytomegalovirus (CMV) vaccine
Trial: 25200403
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg daily for 8 weeks
Trial: 16411341
Drug: Thai regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thai regimen (zidovudine 300 mg po bid from 36 weeks until labour, zidovudine 300 mg po q3h during labour; neonates received placebo)
Trial: 16411341
Drug: Ultra-Short regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-Short regimen (placebo from 36 weeks to labour, zidovudine 300 mg po q3h in labour; neonates received zidovudine 2 mg/kg po qid for the first three days)
Trial: 9640061
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for tick-borne encephalitis (exact treatment details not provided)
Trial: 17185207
Drug: Contingency contracting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency contracting (CC)
Trial: 7734459
Drug: Medication only/CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only/CC
Trial: 7734459
Drug: Medication only/NC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only/NC
Trial: 2466359
Drug: Oxendolone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxendolone 200 mg weekly
Trial: 31659986
Drug: Stent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent treatment (bare metal stents (BMS) or drug-eluting stents (DES))
Trial: 31659986
Drug: Stent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent treatment (BMS or DES)
Trial: 22623389
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish intake (two 150-g salmon portions/wk)
Trial: 1561466
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN)
Trial: 1561466
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN) for 3 weeks
Trial: 31162103
Drug: Salvage radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiotherapy with short-term hormone therapy
Trial: 31162103
Drug: Salvage radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiotherapy without short-term hormone therapy
Trial: 29665130
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of digoxin (0.25 mg), furosemide (1 mg), metformin (10 mg), and rosuvastatin (10 mg)
Trial: 29665130
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug treatments (digoxin, furosemide, metformin, rosuvastatin)
Trial: 27178366
Drug: Prednisolone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (250 mg)
Trial: 20309531
Drug: Nicotine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (21 mg)
Trial: 8756050
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 500 mg quinine base
Trial: 8756050
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 500 mg quinine base
Trial: 26049126
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT), 4 sessions
Trial: 24075759
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100,000 units oral)
Trial: 15031570
Drug: BiPAP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP plus standard therapy (group 1)
Trial: 15031570
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (group 2)
Trial: 3710290
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (PK 10169)
Trial: 29456149
Drug: Universal Medication
RxNorm normalized name: STATLOCK UNIVERSAL PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal Medication Schedule (UMS)
Trial: 17472802
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment options for ARMD
Trial: 16120062
Drug: 0.375 mg
RxNorm normalized name: vitamin A 0.375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375 mg triazolam
Trial: 368088
Drug: Oxprenolol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (180 to 480 mg daily)
Trial: 368088
Drug: Propranolol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (180 to 480 mg daily)
Trial: 30036571
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 µg/kg/day i.v. from day 7 post-transplant until neutrophil recovery
Trial: 24762094
Drug: Dulaglutide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 2.0 mg
Trial: 11880966
Drug: d4T-3TC-NFV (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d4T-3TC-NFV (3 times daily)
Trial: 10452470
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid emulsion (1.0 mg/kg per day)
Trial: 10452470
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B dextrose (0.5 mg/kg per day)
Trial: 7872342
Drug: ACEI (enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (enalapril or lisinopril)
Trial: 2222130
Drug: 25% per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% per week taper of short half-life benzodiazepines
Trial: 2222130
Drug: 25% per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% per week taper of long half-life benzodiazepines
Trial: 30611640
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous distilled water)
Trial: 23863909
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of GAD-alum (4D)
Trial: 23863909
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of GAD-alum (2D)
Trial: 19343928
Drug: EDTA followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA followed by NaOCl treatment
Trial: 15037686
Drug: Nasal sumatriptan
RxNorm normalized name: sumatriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal sumatriptan (10 mg for 20-39 kg; 20 mg for >40 kg)
Trial: 10460981
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment on other foot zones
Trial: 2329393
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine oral rinse used as a preoperative rinse and immediate postextraction irrigant
Trial: 7247088
Drug: Subcutaneous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous epinephrine combined with aerosol placebo
Trial: 26869148
Drug: l-theanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-theanine (200 mg)
Trial: 26869148
Drug: caffeine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caffeine (160 mg)
Trial: 26869148
Drug: theanine-caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: theanine-caffeine combination
Trial: 23727083
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg vs Atorvastatin 10 mg
Trial: 21856001
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intravenous ramosetron (group A)
Trial: 21856001
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg oral ramosetron (group B)
Trial: 21856001
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.1 mg oral and 0.3 mg intravenous ramosetron (group C)
Trial: 10574168
Drug: Control Therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Therapy (CT)
Trial: 17920916
Drug: Reduced-intensity stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)
Trial: 15277909
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 mg orally and as a patch) administered the night before surgery and on the morning of surgery
Trial: 11504278
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg (Days 1-7) and 400 mg (Days 8-28)
Trial: 11504278
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg and 400 mg + Methylphenidate 20 mg (Days 22-28)
Trial: 8536887
Drug: Budesonide 6
RxNorm normalized name: budesonide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 6 mg daily
Trial: 8536887
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg daily
Trial: 8160597
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (amiodarone or sotalol)
Trial: 23870670
Drug: Ragweed MATA
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L‐Tyrosine + MPL)
Trial: 10793597
Drug: Fenoterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (10 puffs via metered dose inhaler)
Trial: 10793597
Drug: Ipratropium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (10 puffs via metered dose inhaler)
Trial: 8762211
Drug: Nifedipine gastrointestinal
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine gastrointestinal therapeutic system (30 mg/day)
Trial: 8762211
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard (20 mg twice a day)
Trial: 29517671
Drug: McGrath videolaryngoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McGrath videolaryngoscope (ML group)
Trial: 7617471
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NCR) at doses of 1.0 mg, 1/4 mg, 1/16 mg, or 1/64 mg
Trial: 2239717
Drug: Theophylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (400 mg twice a day)
Trial: 2856902
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg twice a day)
Trial: 2239717
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (theophylline and atenolol)
Trial: 684774
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy combined with external irradiation
Trial: 31786983
Drug: Esaxerenone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone 2.5 mg/day
Trial: 31786983
Drug: Esaxerenone 5
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Esaxerenone 5 mg/day
Trial: 31074576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly automated phone message reminders)
Trial: 30392473
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g refined cold-pressed flaxseed oil providing 4.7 g ALA (n 29)
Trial: 30392473
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g high-oleic sunflower oil as control (n 30)
Trial: 28913833
Drug: Conjoint family‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint family‐based treatment (FBT)
Trial: 28913833
Drug: Parent‐focused treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent‐focused treatment (PFT)
Trial: 19203564
Drug: 0.03% meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% meloxicam solution (1 drop t.i.d. for 30 days)
Trial: 19203564
Drug: 0.1% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% diclofenac solution (1 drop t.i.d. for 30 days)
Trial: 17577461
Drug: CS-706 10
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-706 10 mg
Trial: 17577461
Drug: CS-706 50
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-706 50 mg
Trial: 17577461
Drug: CS-706 100
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-706 100 mg
Trial: 17577461
Drug: CS-706 200
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-706 200 mg
Trial: 12561647
Drug: Allergenic extract
RxNorm normalized name: ALLERGENIC EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergenic extract pollen Cynodon dactylon (L) Pers skin prick test
Trial: 9660536
Drug: Intermittent schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent schedule (IS), oral administration of UFT (130 mg/m2/b.i.d.) with 2 days rest a week
Trial: 9660536
Drug: Continuous schedule
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous schedule (CS), consecutive administration of UFT (130 mg/m2/b.i.d.)